Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer
- Conditions
- Dyspnea associated with Cancer
- Registration Number
- JPRN-UMIN000005853
- Lead Sponsor
- Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Not provided
I. The first stage 1) Hypersensitivity reactions to furosemide, opioids and sulfonamide derivatives 2) Severe heart failure, respiratory disease with unstable dyspnea 3) Neurological, mental impairment with the difficulty of collecting data 4) Drug abuse, drug dependence 5) Pregnancy, lactation II. The second stage 1) Inability to take oral rapid onset morphine 2) Pain score above 3 3) Severe hypertention(SBP >= 180mmHg or DBP >= 110mmHg) 4) Liver failure, renal failure AST(GOT) >= 100IU/L ALT(GPT) >= 100IU/L T.bil >= 2.0mg/dL eGFR <= 30 mL/hr 5) Severe respiratory failure or the administration of oxygen with flow rate of 10L/min or more 6) Ineligible condition for study in physician's judge 7) The change in prescription of opioid, steroids and anxiolytics within 2 days prior to study 8) The change in the chemotherapy within 7 days prior to study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The worst dyspneic sensation as measured on NRS between on the previous day of the treatment and on the final day of the treatment
- Secondary Outcome Measures
Name Time Method